| Enzalutamide with standard first-line therapy in metastatic prostate cancer ID Davis, AJ Martin, MR Stockler, S Begbie, KN Chi, S Chowdhury, ... New England Journal of Medicine 381 (2), 121-131, 2019 | 1433 | 2019 |
| [177Lu] Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial MS Hofman, L Emmett, S Sandhu, A Iravani, AM Joshua, JC Goh, ... The Lancet 397 (10276), 797-804, 2021 | 759 | 2021 |
| Change in neutrophil-to-lymphocyte ratio in response to targeted therapy for metastatic renal cell carcinoma as a prognosticator and biomarker of efficacy AJ Templeton, JJ Knox, X Lin, R Simantov, W Xie, N Lawrence, R Broom, ... European urology 70 (2), 358-364, 2016 | 173 | 2016 |
| Wnt signalling: a theme with nuclear variations C Sharpe, N Lawrence, AM Arias Bioessays 23 (4), 311-318, 2001 | 165 | 2001 |
| PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu] Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP … JP Buteau, AJ Martin, L Emmett, A Iravani, S Sandhu, AM Joshua, ... The Lancet Oncology 23 (11), 1389-1397, 2022 | 156 | 2022 |
| TheraP: a randomized phase 2 trial of 177Lu‐PSMA‐617 theranostic treatment vs cabazitaxel in progressive metastatic castration‐resistant prostate cancer … MS Hofman, L Emmett, J Violet, A Y. Zhang, NJ Lawrence, M Stockler, ... BJU international 124, 5-13, 2019 | 148 | 2019 |
| Planar polarity and actin dynamics in the epidermis of Drosophila JA Kaltschmidt, N Lawrence, V Morel, T Balayo, BG Fernández, ... Nature cell biology 4 (12), 937-944, 2002 | 145 | 2002 |
| ENZAMET Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group. Enzalutamide with standard first-line therapy in metastatic prostate … ID Davis, AJ Martin, MR Stockler, S Begbie, KN Chi, S Chowdhury, ... N Engl J Med 381 (2), 121-131, 2019 | 135 | 2019 |
| Factors influencing concordance with compression stockings after venous leg ulcer healing AB Jull, N Mitchell, J Aroll, M Jones, J Waters, A Latta, N Walker, B Aroll Journal of Wound Care 13 (3), 90-92, 2004 | 109 | 2004 |
| Self-establishing communities enable cooperative metabolite exchange in a eukaryote K Campbell, J Vowinckel, M Mülleder, S Malmsheimer, N Lawrence, ... Elife 4, e09943, 2015 | 107 | 2015 |
| Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an … CJ Sweeney, AJ Martin, MR Stockler, S Begbie, L Cheung, KN Chi, ... The Lancet Oncology 24 (4), 323-334, 2023 | 103 | 2023 |
| Structural requirements for Notch signalling with Delta and Serrate during the development and patterning of the wing disc of Drosophila N Lawrence, T Klein, K Brennan, AM Arias Development 127 (14), 3185-3195, 2000 | 96 | 2000 |
| Efficacy and safety of telaglenastat plus cabozantinib vs placebo plus cabozantinib in patients with advanced renal cell carcinoma: the CANTATA randomized clinical trial NM Tannir, N Agarwal, C Porta, NJ Lawrence, R Motzer, B McGregor, ... JAMA oncology 8 (10), 1411-1418, 2022 | 86 | 2022 |
| Notch signaling targets the Wingless responsiveness of a Ubx visceral mesoderm enhancer in Drosophila N Lawrence, T Langdon, K Brennan, AM Arias Current Biology 11 (6), 375-385, 2001 | 59 | 2001 |
| Separating Golgi Proteins from Cis to Trans Reveals Underlying Properties of Cisternal Localization HT Parsons, TJ Stevens, HE McFarlane, S Vidal-Melgosa, J Griss, ... The Plant Cell 31 (9), 2010-2034, 2019 | 57 | 2019 |
| PALB2 chromatin recruitment restores homologous recombination in BRCA1-deficient cells depleted of 53BP1 R Belotserkovskaya, E Raga Gil, N Lawrence, R Butler, G Clifford, ... Nature communications 11 (1), 819, 2020 | 54 | 2020 |
| Mice with skin-specific DNA repair gene (Ercc1) inactivation are hypersensitive to ultraviolet irradiation-induced skin cancer and show more rapid actinic progression J Doig, C Anderson, NJ Lawrence, J Selfridge, DG Brownstein, ... Oncogene 25 (47), 6229-6238, 2006 | 53 | 2006 |
| Updated overall survival outcomes in ENZAMET (ANZUP 1304), an international, cooperative group trial of enzalutamide in metastatic hormone-sensitive prostate cancer (mHSPC). ID Davis, AJ Martin, RR Zielinski, A Thomson, TH Tan, S Sandhu, ... Journal of Clinical Oncology 40 (17_suppl), LBA5004-LBA5004, 2022 | 50 | 2022 |
| Characterizing the impact of lymph node metastases on the survival outcome for metastatic renal cell carcinoma patients treated with targeted therapies N Kroeger, AJ Pantuck, JC Wells, N Lawrence, R Broom, JJ Kim, ... European urology 68 (3), 506-515, 2015 | 49 | 2015 |
| Overall survival of men with metachronous metastatic hormone-sensitive prostate cancer treated with enzalutamide and androgen deprivation therapy CJ Sweeney, AJ Martin, MR Stockler, S Begbie, KN Chi, S Chowdhury, ... European Urology 80 (3), 275-279, 2021 | 47 | 2021 |
